Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
Background - Effective treatments are needed to improve outcomes for high-grade glioma and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated in adult patients with recurrent or progressive BRAFV600E mutation-positive high-grade glioma and low-grade glioma. - Meth...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
January 2022
|
| In: |
The lancet. Oncology
Year: 2022, Volume: 23, Issue: 1, Pages: 53-64 |
| ISSN: | 1474-5488 |
| DOI: | 10.1016/S1470-2045(21)00578-7 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/S1470-2045(21)00578-7 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1470204521005787 
|
| Author Notes: | Patrick Y Wen, Alexander Stein, Martin van den Bent, Jacques De Greve, Antje Wick, Filip Y F L de Vos, Nikolas von Bubnoff, Myra E van Linde, Albert Lai, Gerald W Prager, Mario Campone, Angelica Fasolo, Jose A Lopez-Martin, Tae Min Kim, Warren P Mason, Ralf-Dieter Hofheinz, Jean-Yves Blay, Daniel C Cho, Anas Gazzah, Damien Pouessel, Jeffrey Yachnin, Aislyn Boran, Paul Burgess, Palanichamy Ilankumaran, Eduard Gasal, Vivek Subbiah |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1837101566 | ||
| 003 | DE-627 | ||
| 005 | 20230706232632.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230220s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(21)00578-7 |2 doi | |
| 035 | |a (DE-627)1837101566 | ||
| 035 | |a (DE-599)KXP1837101566 | ||
| 035 | |a (OCoLC)1389535405 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wen, Patrick Y. |e VerfasserIn |0 (DE-588)1205842608 |0 (DE-627)1691570818 |4 aut | |
| 245 | 1 | 0 | |a Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR) |b a multicentre, open-label, single-arm, phase 2, basket trial |c Patrick Y Wen, Alexander Stein, Martin van den Bent, Jacques De Greve, Antje Wick, Filip Y F L de Vos, Nikolas von Bubnoff, Myra E van Linde, Albert Lai, Gerald W Prager, Mario Campone, Angelica Fasolo, Jose A Lopez-Martin, Tae Min Kim, Warren P Mason, Ralf-Dieter Hofheinz, Jean-Yves Blay, Daniel C Cho, Anas Gazzah, Damien Pouessel, Jeffrey Yachnin, Aislyn Boran, Paul Burgess, Palanichamy Ilankumaran, Eduard Gasal, Vivek Subbiah |
| 246 | 3 | 3 | |a Dabrafenib plus trametinib in patients with BRAF V600E - mutant low-grade and high-grade glioma (ROAR) |
| 264 | 1 | |c January 2022 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar 24 November 2021, Artikelversion 29 Dezember 2021 | ||
| 500 | |a Gesehen am 20.02.2023 | ||
| 500 | |a Im Titel ist der Ausdruck "V600E" hochgestellt | ||
| 520 | |a Background - Effective treatments are needed to improve outcomes for high-grade glioma and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated in adult patients with recurrent or progressive BRAFV600E mutation-positive high-grade glioma and low-grade glioma. - Methods - This study is part of an ongoing open-label, single-arm, phase 2 Rare Oncology Agnostic Research (ROAR) basket trial at 27 community and academic cancer centres in 13 countries (Austria, Belgium, Canada, France, Germany, Italy, Japan, the Netherlands, Norway, South Korea, Spain, Sweden, and the USA). The study enrolled patients aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0, 1, or 2. Patients with BRAFV600E mutation-positive high-grade glioma and low-grade glioma received dabrafenib 150 mg twice daily plus trametinib 2 mg once daily orally until unacceptable toxicity, disease progression, or death. In the high-grade glioma cohort, patients were required to have measurable disease at baseline using the Response Assessment in Neuro-Oncology high-grade glioma response criteria and have been treated previously with radiotherapy and first-line chemotherapy or concurrent chemoradiotherapy. Patients with low-grade glioma were required to have measurable non-enhancing disease (except pilocytic astrocytoma) at baseline using the Response Assessment in Neuro-Oncology low-grade glioma criteria. The primary endpoint, in the evaluable intention-to-treat population, was investigator-assessed objective response rate (complete response plus partial response for high-grade glioma and complete response plus partial response plus minor response for low-grade glioma). This trial is ongoing, but is closed for enrolment, NCT02034110. - Findings - Between April 17, 2014, and July 25, 2018, 45 patients (31 with glioblastoma) were enrolled into the high-grade glioma cohort and 13 patients were enrolled into the low-grade glioma cohort. The results presented here are based on interim analysis 16 (data cutoff Sept 14, 2020). In the high-grade glioma cohort, median follow-up was 12·7 months (IQR 5·4-32·3) and 15 (33%; 95% CI 20-49) of 45 patients had an objective response by investigator assessment, including three complete responses and 12 partial responses. In the low-grade glioma cohort, median follow-up was 32·2 months (IQR 25·1-47·8). Nine (69%; 95% CI 39-91) of 13 patients had an objective response by investigator assessment, including one complete response, six partial responses, and two minor responses. Grade 3 or worse adverse events were reported in 31 (53%) patients, the most common being fatigue (five [9%]), decreased neutrophil count (five [9%]), headache (three [5%]), and neutropenia (three [5%]). - Interpretation - Dabrafenib plus trametinib showed clinically meaningful activity in patients with BRAFV600E mutation-positive recurrent or refractory high-grade glioma and low-grade glioma, with a safety profile consistent with that in other indications. BRAFV600E testing could potentially be adopted in clinical practice for patients with glioma. - Funding - Novartis. | ||
| 700 | 1 | |a Stein, Alexander |e VerfasserIn |4 aut | |
| 700 | 1 | |a van den Bent, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a De Greve, Jacques |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wick, Antje |d 1972- |e VerfasserIn |0 (DE-588)122759869 |0 (DE-627)706032101 |0 (DE-576)293409609 |4 aut | |
| 700 | 1 | |a de Vos, Filip Y F L |e VerfasserIn |4 aut | |
| 700 | 1 | |a von Bubnoff, Nikolas |e VerfasserIn |4 aut | |
| 700 | 1 | |a van Linde, Myra E |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lai, Albert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Prager, Gerald W |e VerfasserIn |4 aut | |
| 700 | 1 | |a Campone, Mario |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fasolo, Angelica |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lopez-Martin, Jose A |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kim, Tae Min |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mason, Warren P |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 700 | 1 | |a Blay, Jean-Yves |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cho, Daniel C |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gazzah, Anas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pouessel, Damien |e VerfasserIn |4 aut | |
| 700 | 1 | |a Yachnin, Jeffrey |e VerfasserIn |4 aut | |
| 700 | 1 | |a Boran, Aislyn |e VerfasserIn |4 aut | |
| 700 | 1 | |a Burgess, Paul |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ilankumaran, Palanichamy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gasal, Eduard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Subbiah, Vivek |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet. Oncology |d London : The Lancet Publ. Group, 2000 |g 23(2022), 1 vom: Jan., Seite 53-64 |h Online-Ressource |w (DE-627)325349770 |w (DE-600)2035574-9 |w (DE-576)100517544 |x 1474-5488 |7 nnas |a Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR) a multicentre, open-label, single-arm, phase 2, basket trial |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:1 |g month:01 |g pages:53-64 |g extent:12 |a Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR) a multicentre, open-label, single-arm, phase 2, basket trial |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S1470-2045(21)00578-7 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S1470204521005787 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230220 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 61200 |e 60000PH121917517 |e 61200PH121917517 |k 0/60000/ |k 1/60000/61200/ |p 16 | ||
| 998 | |g 122759869 |a Wick, Antje |m 122759869:Wick, Antje |d 910000 |d 911100 |d 50000 |e 910000PW122759869 |e 911100PW122759869 |e 50000PW122759869 |k 0/910000/ |k 1/910000/911100/ |k 0/50000/ |p 5 | ||
| 999 | |a KXP-PPN1837101566 |e 4274878791 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR)","title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR)","subtitle":"a multicentre, open-label, single-arm, phase 2, basket trial"}],"language":["eng"],"person":[{"family":"Wen","role":"aut","given":"Patrick Y.","display":"Wen, Patrick Y."},{"display":"Stein, Alexander","given":"Alexander","role":"aut","family":"Stein"},{"display":"van den Bent, Martin","role":"aut","given":"Martin","family":"van den Bent"},{"display":"De Greve, Jacques","role":"aut","given":"Jacques","family":"De Greve"},{"family":"Wick","role":"aut","given":"Antje","display":"Wick, Antje"},{"family":"de Vos","role":"aut","given":"Filip Y F L","display":"de Vos, Filip Y F L"},{"display":"von Bubnoff, Nikolas","role":"aut","given":"Nikolas","family":"von Bubnoff"},{"role":"aut","given":"Myra E","display":"van Linde, Myra E","family":"van Linde"},{"family":"Lai","display":"Lai, Albert","given":"Albert","role":"aut"},{"display":"Prager, Gerald W","given":"Gerald W","role":"aut","family":"Prager"},{"display":"Campone, Mario","role":"aut","given":"Mario","family":"Campone"},{"role":"aut","given":"Angelica","display":"Fasolo, Angelica","family":"Fasolo"},{"family":"Lopez-Martin","role":"aut","given":"Jose A","display":"Lopez-Martin, Jose A"},{"given":"Tae Min","role":"aut","display":"Kim, Tae Min","family":"Kim"},{"family":"Mason","display":"Mason, Warren P","role":"aut","given":"Warren P"},{"family":"Hofheinz","given":"Ralf-Dieter","role":"aut","display":"Hofheinz, Ralf-Dieter"},{"family":"Blay","role":"aut","given":"Jean-Yves","display":"Blay, Jean-Yves"},{"family":"Cho","role":"aut","given":"Daniel C","display":"Cho, Daniel C"},{"family":"Gazzah","display":"Gazzah, Anas","role":"aut","given":"Anas"},{"family":"Pouessel","display":"Pouessel, Damien","role":"aut","given":"Damien"},{"family":"Yachnin","display":"Yachnin, Jeffrey","role":"aut","given":"Jeffrey"},{"family":"Boran","display":"Boran, Aislyn","given":"Aislyn","role":"aut"},{"family":"Burgess","display":"Burgess, Paul","role":"aut","given":"Paul"},{"family":"Ilankumaran","given":"Palanichamy","role":"aut","display":"Ilankumaran, Palanichamy"},{"family":"Gasal","role":"aut","given":"Eduard","display":"Gasal, Eduard"},{"given":"Vivek","role":"aut","display":"Subbiah, Vivek","family":"Subbiah"}],"name":{"displayForm":["Patrick Y Wen, Alexander Stein, Martin van den Bent, Jacques De Greve, Antje Wick, Filip Y F L de Vos, Nikolas von Bubnoff, Myra E van Linde, Albert Lai, Gerald W Prager, Mario Campone, Angelica Fasolo, Jose A Lopez-Martin, Tae Min Kim, Warren P Mason, Ralf-Dieter Hofheinz, Jean-Yves Blay, Daniel C Cho, Anas Gazzah, Damien Pouessel, Jeffrey Yachnin, Aislyn Boran, Paul Burgess, Palanichamy Ilankumaran, Eduard Gasal, Vivek Subbiah"]},"id":{"eki":["1837101566"],"doi":["10.1016/S1470-2045(21)00578-7"]},"physDesc":[{"extent":"12 S."}],"note":["Online verfügbar 24 November 2021, Artikelversion 29 Dezember 2021","Gesehen am 20.02.2023","Im Titel ist der Ausdruck \"V600E\" hochgestellt"],"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"The lancet <London> / Oncology"}],"origin":[{"publisherPlace":"London","dateIssuedKey":"2000","dateIssuedDisp":"2000-","publisher":"The Lancet Publ. Group"}],"recId":"325349770","note":["Gesehen am 22.09.2021"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR) a multicentre, open-label, single-arm, phase 2, basket trialThe lancet. Oncology","id":{"zdb":["2035574-9"],"issn":["1474-5488"],"eki":["325349770"]},"part":{"volume":"23","year":"2022","text":"23(2022), 1 vom: Jan., Seite 53-64","extent":"12","pages":"53-64","issue":"1"},"language":["eng"],"title":[{"title_sort":"lancet","partname":"Oncology","title":"The lancet"}],"pubHistory":["0.2000 -"]}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"titleAlt":[{"title":"Dabrafenib plus trametinib in patients with BRAF V600E - mutant low-grade and high-grade glioma (ROAR)"}],"origin":[{"dateIssuedDisp":"January 2022","dateIssuedKey":"2022"}],"recId":"1837101566"} | ||
| SRT | |a WENPATRICKDABRAFENIB2022 | ||